AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US

AstraZeneca's (AZN) third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of$ 1.01 per share. Core earnings of $2.08 per share fell 20% year over year on a reported basis and 27% at constant exchange rates (CER). Total revenues of$ 13.57 billion rose 18% on a reported basis and 21% at CER, driven by higher product sales and alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $13.04 billion. All growth rates ...